H.C. Wainwright lowered the firm’s price target on ALX Oncology (ALXO) to $2 from $5 and keeps a Buy rating on the shares. The company announced its decision to discontinue the development of evorpacept in gastric and gastroesophageal cancers based on the FDA’s feedback, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology Reports Q1 2025 Financial Results
- ALX Oncology reports Q1 EPS (58c) vs (71c) last year
- ALX Oncology price target lowered to $1.20 from $2.20 at UBS
- ALX Oncology reports ‘encouraging’ final results from Phase 1 evorpacept trial
- ALX Oncology reports ASPEN-03, ASPEN-04 trials did not meet primary endpoints